Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162744 | 0.87 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL31130328 | 0.86 | RAB9A (0.50) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL1869059 | 0.85 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL4405770 | 0.82 | BCL2L1 (0.57) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL29913871 | 0.82 | BCL2L1 (0.57) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL5163196 | 0.82 | HDAC3 (0.51) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL5161974 | 0.82 | HDAC3 (0.51) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL5163526 | 0.80 | HDAC3 (0.53) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL3608307 | 0.80 | HDAC3 (0.60) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL6334117 | 0.80 | BCL2L1 (0.62) | HDAC3HDAC1HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822945-B1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B V (NL) | 2019-06-19 | — | — | EP | disclosed |
| US-10071987-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2018-09-11 | — | — | US | disclosed |
| US-20180030035-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2018-02-01 | — | — | US | disclosed |
| US-9790205-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2017-10-17 | — | — | US | disclosed |
| US-20170240531-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2017-08-24 | — | — | US | disclosed |
| US-9676764-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2017-06-13 | — | — | US | disclosed |
| US-20160326152-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2016-11-10 | — | — | US | disclosed |
| US-9453012-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2016-09-27 | — | — | US | disclosed |
| US-20150073019-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | SPECS COMPOUND HANDLING B.V. (NL) | 2015-03-12 | — | — | US | disclosed |
| EP-2822945-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | Compound Handling B.V. (NL) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013131931-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2013-09-12 | — | — | WO | disclosed |
| US-8293899-B2 | Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates | LANXESS DEUTSCHLAND GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030035-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | HDAC3 7/4885HDAC1 49/4885HDAC2 243/4885 |
| US-10071987-B2 | Aminomethylene pyrazolones with therapeutic activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | HDAC3 7/4885HDAC1 49/4885HDAC2 243/4885 |
| US-20170240531-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | HDAC3 9/4885HDAC1 51/4885HDAC2 261/4885 |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | GRHPR, HPD, HAAO | HDAC3 123/4885HDAC1 1196/4885HDAC2 394/4885 |
| US-20160326152-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | HDAC3 9/4885HDAC1 51/4885HDAC2 261/4885 |
| US-20150073019-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | HDAC3 9/4885HDAC1 51/4885HDAC2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.